Abstract | BACKGROUND: In the Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease, all patients were at high cardiovascular risk, and a substantial proportion were hypertensive. We performed a post-hoc analysis to explore the hypothesis that telmisartan has a differential action in hypertensive vs. nonhypertensive patients. METHODS: RESULTS: There was no evidence for a significantly differential treatment effect of telmisartan in hypertensive and nonhypertensive patients for any endpoints, although the occurrence of the secondary three-fold endpoint was significantly lower in the telmisartan group (13.0%) compared with placebo (15.0%, P < 0.05) only in hypertensive patients. Moreover, data from this post-hoc analysis suggest that MI may be less frequent in hypertensive patients treated with telmisartan (3.8 vs. 5.1%; P < 0.05). Telmisartan may also reduce new onset of LVH (nonhypertensive patients P < 0.05; hypertensive patients P < 0.001) in both subgroups, and new onset of microalbuminuria and macroalbuminuria in hypertensive patients (P < 0.001 and P < 0.01, respectively).The effect of telmisartan in hypertensive and nonhypertensive patients at high cardiovascular risk was not different. This post-hoc analysis suggests that MI may be further reduced by telmisartan in hypertensive patients. Further investigations are needed to study the hypotheses raised by this explanatory analysis.
|
Authors | Sébastien Foulquier, Michael Böhm, Roland Schmieder, Peter Sleight, Koon Teo, Salim Yusuf, Helmut Schumacher, Thomas Unger |
Journal | Journal of hypertension
(J Hypertens)
Vol. 32
Issue 6
Pg. 1334-41
(Jun 2014)
ISSN: 1473-5598 [Electronic] England |
PMID | 24621807
(Publication Type: Journal Article, Observational Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antihypertensive Agents
- Benzimidazoles
- Benzoates
- Telmisartan
|
Topics |
- Aged
- Antihypertensive Agents
(therapeutic use)
- Benzimidazoles
(therapeutic use)
- Benzoates
(therapeutic use)
- Cardiovascular Diseases
(prevention & control)
- Cardiovascular System
(drug effects)
- Coronary Artery Disease
(drug therapy)
- Female
- Follow-Up Studies
- Heart Failure
(prevention & control)
- Hospitalization
- Humans
- Hypertension
(drug therapy)
- Hypertrophy, Left Ventricular
(complications)
- Male
- Middle Aged
- Myocardial Infarction
(prevention & control)
- Peripheral Vascular Diseases
(drug therapy)
- Stroke
(prevention & control)
- Telmisartan
- Treatment Outcome
|